摘要
目的:探讨Sestrin3在子宫内膜样腺癌中的表达及临床意义。方法:收集2010年4月—2015年4月期间于川北医学院附属医院经病理确诊的93例子宫内膜样腺癌患者组织标本及临床资料,同时选取同期增殖期子宫内膜组织标本30例及子宫内膜增生不伴非典型性、子宫内膜增生伴非典型性组织标本各40例作为对照组,通过免疫组织化学法检测各子宫内膜组织中Sestrin3的表达情况,分析Sestrin3在子宫内膜样腺癌中的表达情况与不同临床特征及预后的相关性。结果:Sestrin3在子宫内膜增生伴非典型性、子宫内膜样腺癌组织中的表达明显低于在增殖期子宫内膜、子宫内膜增生不伴非典型性组织中的表达,且Sestrin3的表达与子宫内膜样腺癌组织学分级相关(P<0.05),而与年龄、肌层浸润深度、淋巴结转移、FIGO分期及患者生存时间无相关性(P>0.05)。结论:Sestrin3在子宫内膜样腺癌发生、发展过程中可能发挥了抑癌基因的作用,其表达降低可能促进了子宫内膜样腺癌的进展。
Objective:To investigate the expression and clinical significance of Sestrin3 in endometrial carcinoma.Methods:Collected 93 cases of endometrioid adenocarcinoma(EA),30 cases of proliferative phase of endometrium(PE),40 cases of endometrial hyperplasia without atypia(EH),and 40 cases of atypical endometrial hyperplasia(AEH)from April 2010 to April 2015 in Pathology department of Affiliated Hospital of North Sichuan Medical College.The expresstion of Sestrin3 in these tissues was detected by immunohistochemistry.Moreover,the association between Sestrin3 expression and clinicopathological characteristics was analyzed.Results:The positive rates of Sestrin3 in AEH and EA tissues were significantly lower than that in PE and EH tissues(P<0.05).In EA tisseues,the expression of Sestrin3 was related to the pathological grade(P<0.05),but it was not statistically related to the age,myometrial invasion,lymph node metastasis,FIGO stages and patients survuval time(P>0.05).Conclusion:Sestrin3 may play a tumor suppressor gene role in oncogenesis and development of endometrioid adenocarcinoma.The reduced expression of Sestrin3 may accelerate the development of endometrioid adenocarcinoma.
作者
高佩璐
刘钧
GAO Peilu;LIU Jun(North Sichuan Medical College,Nanchong City,Sichuan Province 637100)
出处
《医学理论与实践》
2021年第3期380-382,共3页
The Journal of Medical Theory and Practice
